Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 285 entries
Sorted by: Best Match Show Resources per page
XPS characterization of (copper-based) coloured stains formed on limestone surfaces of outdoor Roman monuments.

Chemistry Central journal

Salvi AM, Langerame F, Macchia A, Sammartino MP, Tabasso ML.
PMID: 22594435
Chem Cent J. 2012 May 02;6:S10. doi: 10.1186/1752-153X-6-S2-S10.

Limestone basements holding bronzes or other copper alloys artefacts such as sculptures, decorations and dedicatory inscriptions are frequently met both in modern and ancient monuments. In outdoor conditions, such a combination implies the corrosion products of the copper based...

Cite
Salvi AM, Langerame F, Macchia A, et al. XPS characterization of (copper-based) coloured stains formed on limestone surfaces of outdoor Roman monuments. Chem Cent J. 2012;6:S10doi: 10.1186/1752-153X-6-S2-S10.
Salvi, A. M., Langerame, F., Macchia, A., Sammartino, M. P., & Tabasso, M. L. (2012). XPS characterization of (copper-based) coloured stains formed on limestone surfaces of outdoor Roman monuments. Chemistry Central journal, 6S10. https://doi.org/10.1186/1752-153X-6-S2-S10
Salvi, Anna Maria, et al. "XPS characterization of (copper-based) coloured stains formed on limestone surfaces of outdoor Roman monuments." Chemistry Central journal vol. 6 (2012): S10. doi: https://doi.org/10.1186/1752-153X-6-S2-S10
Salvi AM, Langerame F, Macchia A, Sammartino MP, Tabasso ML. XPS characterization of (copper-based) coloured stains formed on limestone surfaces of outdoor Roman monuments. Chem Cent J. 2012 May 02;6:S10. doi: 10.1186/1752-153X-6-S2-S10. PMID: 22594435; PMCID: PMC3342129.
Copy Download .nbib Format: NLM
Crystallization to polycrystalline silicon thin film and simultaneous inactivation of electrical defects by underwater laser annealing.

Applied physics letters

Machida E, Horita M, Ishikawa Y, Uraoka Y, Ikenoue H.
PMID: 23319827
Appl Phys Lett. 2012 Dec 17;101(25):252106. doi: 10.1063/1.4772513. Epub 2012 Dec 19.

We propose a low-temperature laser annealing method of a underwater laser annealing (WLA) for polycrystalline silicon (poly-Si) films. We performed crystallization to poly-Si films by laser irradiation in flowing deionized-water where KrF excimer laser was used for annealing. We...

Cite
Machida E, Horita M, Ishikawa Y, et al. Crystallization to polycrystalline silicon thin film and simultaneous inactivation of electrical defects by underwater laser annealing. Appl Phys Lett. 2012;101(25):252106doi: 10.1063/1.4772513.
Machida, E., Horita, M., Ishikawa, Y., Uraoka, Y., & Ikenoue, H. (2012). Crystallization to polycrystalline silicon thin film and simultaneous inactivation of electrical defects by underwater laser annealing. Applied physics letters, 101(25), 252106. https://doi.org/10.1063/1.4772513
Machida, Emi, et al. "Crystallization to polycrystalline silicon thin film and simultaneous inactivation of electrical defects by underwater laser annealing." Applied physics letters vol. 101,25 (2012): 252106. doi: https://doi.org/10.1063/1.4772513
Machida E, Horita M, Ishikawa Y, Uraoka Y, Ikenoue H. Crystallization to polycrystalline silicon thin film and simultaneous inactivation of electrical defects by underwater laser annealing. Appl Phys Lett. 2012 Dec 17;101(25):252106. doi: 10.1063/1.4772513. Epub 2012 Dec 19. PMID: 23319827; PMCID: PMC3537686.
Copy Download .nbib Format: NLM
Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Human genomics and proteomics : HGP

Squassina A, Manchia M, Del Zompo M.
PMID: 20981231
Hum Genomics Proteomics. 2010 Aug 03;2010:159761. doi: 10.4061/2010/159761.

Bipolar disorder (BD) is a chronic and often severe psychiatric illness characterized by manic and depressive episodes. Among the most effective treatments, mood stabilizers represent the keystone in acute mania, depression, and maintenance treatment of BD. However, treatment response...

Cite
Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics. 2010;2010:159761doi: 10.4061/2010/159761.
Squassina, A., Manchia, M., & Del Zompo, M. (2010). Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Human genomics and proteomics : HGP, 2010159761. https://doi.org/10.4061/2010/159761
Squassina, Alessio, et al. "Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder." Human genomics and proteomics : HGP vol. 2010 (2010): 159761. doi: https://doi.org/10.4061/2010/159761
Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics. 2010 Aug 03;2010:159761. doi: 10.4061/2010/159761. PMID: 20981231; PMCID: PMC2958627.
Copy Download .nbib Format: NLM
Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence.

Reviews in urology

Carmignani L, Bianchi R, Cozzi G, Grasso A, Macchione N, Marenghi C, Melegari S, Rosso M, Tondelli E, Maggioni A.
PMID: 24659911
Rev Urol. 2013;15(4):145-53.

A review of the literature was performed to summarize current evidence regarding the efficacy of topical immunotherapy and chemotherapy for upper urinary tract urothelial cell carcinoma (UUT-UCC) in terms of post-treatment recurrence rates. A Medline database literature search was...

Cite
Carmignani L, Bianchi R, Cozzi G, et al. Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence. Rev Urol. 2013;15(4):145-53
Carmignani, L., Bianchi, R., Cozzi, G., Grasso, A., Macchione, N., Marenghi, C., Melegari, S., Rosso, M., Tondelli, E., & Maggioni, A. (2013). Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence. Reviews in urology, 15(4), 145-53.
Carmignani, Luca, et al. "Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence." Reviews in urology vol. 15,4 (2013): 145-53.
Carmignani L, Bianchi R, Cozzi G, Grasso A, Macchione N, Marenghi C, Melegari S, Rosso M, Tondelli E, Maggioni A. Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence. Rev Urol. 2013;15(4):145-53. PMID: 24659911; PMCID: PMC3922319.
Copy Download .nbib Format: NLM
Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions.

Oncology letters

Terracciano D, Mazzarella C, Cicalese M, Galzerano S, Apostolico G, DI Carlo A, Mariano A, Cecere C, Macchia V.
PMID: 22966327
Oncol Lett. 2010 May;1(3):465-471. doi: 10.3892/ol_00000082. Epub 2010 May 01.

A panel of tumour markers including carcinoembryonic antigen (CEA), carbohydrate antigen (Ca)15-3, Ca125 and Ca19-9 were measured in the lysate of sediments and in the supernatants of pleural effusions of patients with benign and malignant disease. The tumour markers...

Cite
Terracciano D, Mazzarella C, Cicalese M, et al. Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions. Oncol Lett. 2010;1(3):465-471doi: 10.3892/ol_00000082.
Terracciano, D., Mazzarella, C., Cicalese, M., Galzerano, S., Apostolico, G., DI Carlo, A., Mariano, A., Cecere, C., & Macchia, V. (2010). Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions. Oncology letters, 1(3), 465-471. https://doi.org/10.3892/ol_00000082
Terracciano, Daniela, et al. "Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions." Oncology letters vol. 1,3 (2010): 465-471. doi: https://doi.org/10.3892/ol_00000082
Terracciano D, Mazzarella C, Cicalese M, Galzerano S, Apostolico G, DI Carlo A, Mariano A, Cecere C, Macchia V. Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions. Oncol Lett. 2010 May;1(3):465-471. doi: 10.3892/ol_00000082. Epub 2010 May 01. PMID: 22966327; PMCID: PMC3436410.
Copy Download .nbib Format: NLM
A desensitization protocol for delayed allergy to cytarabine: analysis of two cases.

Postepy dermatologii i alergologii

Albanesi M, Carluccio P, Nico A, Giliberti L, Di Bona D, Caiaffa MF, Specchia G, Macchia L.
PMID: 29760627
Postepy Dermatol Alergol. 2018 Apr;35(2):222-224. doi: 10.5114/ada.2018.75249. Epub 2018 Apr 24.

No abstract available.

Cite
Albanesi M, Carluccio P, Nico A, et al. A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatol Alergol. 2018;35(2):222-224doi: 10.5114/ada.2018.75249.
Albanesi, M., Carluccio, P., Nico, A., Giliberti, L., Di Bona, D., Caiaffa, M. F., Specchia, G., & Macchia, L. (2018). A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy dermatologii i alergologii, 35(2), 222-224. https://doi.org/10.5114/ada.2018.75249
Albanesi, Marcello, et al. "A desensitization protocol for delayed allergy to cytarabine: analysis of two cases." Postepy dermatologii i alergologii vol. 35,2 (2018): 222-224. doi: https://doi.org/10.5114/ada.2018.75249
Albanesi M, Carluccio P, Nico A, Giliberti L, Di Bona D, Caiaffa MF, Specchia G, Macchia L. A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatol Alergol. 2018 Apr;35(2):222-224. doi: 10.5114/ada.2018.75249. Epub 2018 Apr 24. PMID: 29760627; PMCID: PMC5949556.
Copy Download .nbib Format: NLM
Rapid desensitization for brentuximab vedotin (Adceteris.

Clinical and molecular allergy : CMA

Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, Macchia L.
PMID: 30386181
Clin Mol Allergy. 2018 Oct 29;16:22. doi: 10.1186/s12948-018-0100-0. eCollection 2018.

BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgGCASE PRESENTATION: A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead...

Cite
Di Girolamo A, Albanesi M, Sinisi A, et al. Rapid desensitization for brentuximab vedotin (Adceteris. Clin Mol Allergy. 2018;16:22doi: 10.1186/s12948-018-0100-0.
Di Girolamo, A., Albanesi, M., Sinisi, A., Nettis, E., Di Bona, D., Caiaffa, M. F., & Macchia, L. (2018). Rapid desensitization for brentuximab vedotin (Adceteris. Clinical and molecular allergy : CMA, 1622. https://doi.org/10.1186/s12948-018-0100-0
Di Girolamo, Attilio, et al. "Rapid desensitization for brentuximab vedotin (Adceteris." Clinical and molecular allergy : CMA vol. 16 (2018): 22. doi: https://doi.org/10.1186/s12948-018-0100-0
Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, Macchia L. Rapid desensitization for brentuximab vedotin (Adceteris. Clin Mol Allergy. 2018 Oct 29;16:22. doi: 10.1186/s12948-018-0100-0. eCollection 2018. PMID: 30386181; PMCID: PMC6205792.
Copy Download .nbib Format: NLM
A 13-year real-life study on efficacy, safety and biological effects of .

Clinical and molecular allergy : CMA

Albanesi M, Nico A, Sinisi A, Giliberti L, Rossi MP, Rossini M, Kourtis G, Rucco AS, Loconte F, Muolo L, Zurlo M, Di Bona D, Caiaffa MF, Macchia L.
PMID: 29375272
Clin Mol Allergy. 2018 Jan 18;16:2. doi: 10.1186/s12948-017-0079-y. eCollection 2018.

METHODS: Clinical efficacy of VIT was assessed as number and severity of reactions to RESULTS: During the VIT treatment, patients were protected, reporting no reactions or mild reactions in occasion of re-stinging events. This protection was entirely maintained during...

Cite
Albanesi M, Nico A, Sinisi A, et al. A 13-year real-life study on efficacy, safety and biological effects of . Clin Mol Allergy. 2018;16:2doi: 10.1186/s12948-017-0079-y.
Albanesi, M., Nico, A., Sinisi, A., Giliberti, L., Rossi, M. P., Rossini, M., Kourtis, G., Rucco, A. S., Loconte, F., Muolo, L., Zurlo, M., Di Bona, D., Caiaffa, M. F., & Macchia, L. (2018). A 13-year real-life study on efficacy, safety and biological effects of . Clinical and molecular allergy : CMA, 162. https://doi.org/10.1186/s12948-017-0079-y
Albanesi, Marcello, et al. "A 13-year real-life study on efficacy, safety and biological effects of ." Clinical and molecular allergy : CMA vol. 16 (2018): 2. doi: https://doi.org/10.1186/s12948-017-0079-y
Albanesi M, Nico A, Sinisi A, Giliberti L, Rossi MP, Rossini M, Kourtis G, Rucco AS, Loconte F, Muolo L, Zurlo M, Di Bona D, Caiaffa MF, Macchia L. A 13-year real-life study on efficacy, safety and biological effects of . Clin Mol Allergy. 2018 Jan 18;16:2. doi: 10.1186/s12948-017-0079-y. eCollection 2018. PMID: 29375272; PMCID: PMC5774115.
Copy Download .nbib Format: NLM
Definition of fields margins for palliative radiotherapy of pancreatic carcinoma.

Molecular and clinical oncology

Buwenge M, Marinelli A, Deodato F, Macchia G, Wondemagegnhu T, Salah T, Cammelli S, Uddin AFMK, Sumon MA, Donati CM, Cilla S, Morganti AG.
PMID: 29844901
Mol Clin Oncol. 2018 Jun;8(6):715-718. doi: 10.3892/mco.2018.1605. Epub 2018 Apr 12.

The present study aimed to provide practical guidelines for palliative treatment of advanced carcinoma of the pancreas (CAP) with the 2D technique. Fifteen patients with locally advanced CAP consecutively treated with radiation therapy at the Radiation Oncology Center, Research...

Cite
Buwenge M, Marinelli A, Deodato F, et al. Definition of fields margins for palliative radiotherapy of pancreatic carcinoma. Mol Clin Oncol. 2018;8(6):715-718doi: 10.3892/mco.2018.1605.
Buwenge, M., Marinelli, A., Deodato, F., Macchia, G., Wondemagegnhu, T., Salah, T., Cammelli, S., Uddin, A. F. M. K., Sumon, M. A., Donati, C. M., Cilla, S., & Morganti, A. G. (2018). Definition of fields margins for palliative radiotherapy of pancreatic carcinoma. Molecular and clinical oncology, 8(6), 715-718. https://doi.org/10.3892/mco.2018.1605
Buwenge, Milly, et al. "Definition of fields margins for palliative radiotherapy of pancreatic carcinoma." Molecular and clinical oncology vol. 8,6 (2018): 715-718. doi: https://doi.org/10.3892/mco.2018.1605
Buwenge M, Marinelli A, Deodato F, Macchia G, Wondemagegnhu T, Salah T, Cammelli S, Uddin AFMK, Sumon MA, Donati CM, Cilla S, Morganti AG. Definition of fields margins for palliative radiotherapy of pancreatic carcinoma. Mol Clin Oncol. 2018 Jun;8(6):715-718. doi: 10.3892/mco.2018.1605. Epub 2018 Apr 12. PMID: 29844901; PMCID: PMC5958799.
Copy Download .nbib Format: NLM
Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis.

Journal of contemporary brachytherapy

Arcelli A, Buwenge M, Macchia G, Cammelli S, Deodato F, Cilla S, Galuppi A, Panni V, Mattiucci GC, Tagliaferri L, Morganti AG.
PMID: 30911306
J Contemp Brachytherapy. 2019 Feb;11(1):21-27. doi: 10.5114/jcb.2019.82804. Epub 2019 Feb 28.

PURPOSE: Concurrent chemoradiation (CCRT) is the standard curative treatment of anal canal cancer (ACC). The role of a brachytherapy (BRT) boost in this setting is still debated. Therefore, the aim of this analysis was to retrospectively evaluate the clinical...

Cite
Arcelli A, Buwenge M, Macchia G, et al. Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. J Contemp Brachytherapy. 2019;11(1):21-27doi: 10.5114/jcb.2019.82804.
Arcelli, A., Buwenge, M., Macchia, G., Cammelli, S., Deodato, F., Cilla, S., Galuppi, A., Panni, V., Mattiucci, G. C., Tagliaferri, L., & Morganti, A. G. (2019). Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. Journal of contemporary brachytherapy, 11(1), 21-27. https://doi.org/10.5114/jcb.2019.82804
Arcelli, Alessandra, et al. "Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis." Journal of contemporary brachytherapy vol. 11,1 (2019): 21-27. doi: https://doi.org/10.5114/jcb.2019.82804
Arcelli A, Buwenge M, Macchia G, Cammelli S, Deodato F, Cilla S, Galuppi A, Panni V, Mattiucci GC, Tagliaferri L, Morganti AG. Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis. J Contemp Brachytherapy. 2019 Feb;11(1):21-27. doi: 10.5114/jcb.2019.82804. Epub 2019 Feb 28. PMID: 30911306; PMCID: PMC6431102.
Copy Download .nbib Format: NLM
Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis.

Translational oncology

Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V.
PMID: 30237099
Transl Oncol. 2019 Jan;12(1):1-7. doi: 10.1016/j.tranon.2018.08.017. Epub 2018 Sep 17.

BACKGROUND: Presurgical carbohydrate antigen 19-9 (CA19-9) level predicts overall survival (OS) in resected pancreatic adenocarcinoma (PaC). The aim of this pooled analysis was to evaluate if presurgical CA19-9 level can also predict local control (LC) and distant metastasis-free survival...

Cite
Mattiucci GC, Morganti AG, Cellini F, et al. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol. 2018;12(1):1-7doi: 10.1016/j.tranon.2018.08.017.
Mattiucci, G. C., Morganti, A. G., Cellini, F., Buwenge, M., Casadei, R., Farioli, A., Alfieri, S., Arcelli, A., Bertini, F., Calvo, F. A., Cammelli, S., Fuccio, L., Giaccherini, L., Guido, A., Herman, J. M., Macchia, G., Maidment, B. W., Miller, R. C., Minni, F., Regine, W. F., Reni, M., Partelli, S., Falconi, M., & Valentini, V. (2019). Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Translational oncology, 12(1), 1-7. https://doi.org/10.1016/j.tranon.2018.08.017
Mattiucci, Gian Carlo, et al. "Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis." Translational oncology vol. 12,1 (2019): 1-7. doi: https://doi.org/10.1016/j.tranon.2018.08.017
Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol. 2019 Jan;12(1):1-7. doi: 10.1016/j.tranon.2018.08.017. Epub 2018 Sep 17. PMID: 30237099; PMCID: PMC6143718.
Copy Download .nbib Format: NLM
Volumetric modulated arc therapy for treatment of solid tumors: current insights.

OncoTargets and therapy

Macchia G, Deodato F, Cilla S, Cammelli S, Guido A, Ferioli M, Siepe G, Valentini V, Morganti AG, Ferrandina G.
PMID: 28794640
Onco Targets Ther. 2017 Jul 26;10:3755-3772. doi: 10.2147/OTT.S113119. eCollection 2017.

AIM: This article discusses the current use of volumetric modulated arc therapy (VMAT) techniques in clinical practice and reviews the available data from clinical outcome studies in different clinical settings. An overview of available literature about clinical outcomes with...

Cite
Macchia G, Deodato F, Cilla S, et al. Volumetric modulated arc therapy for treatment of solid tumors: current insights. Onco Targets Ther. 2017;10:3755-3772doi: 10.2147/OTT.S113119.
Macchia, G., Deodato, F., Cilla, S., Cammelli, S., Guido, A., Ferioli, M., Siepe, G., Valentini, V., Morganti, A. G., & Ferrandina, G. (2017). Volumetric modulated arc therapy for treatment of solid tumors: current insights. OncoTargets and therapy, 103755-3772. https://doi.org/10.2147/OTT.S113119
Macchia, Gabriella, et al. "Volumetric modulated arc therapy for treatment of solid tumors: current insights." OncoTargets and therapy vol. 10 (2017): 3755-3772. doi: https://doi.org/10.2147/OTT.S113119
Macchia G, Deodato F, Cilla S, Cammelli S, Guido A, Ferioli M, Siepe G, Valentini V, Morganti AG, Ferrandina G. Volumetric modulated arc therapy for treatment of solid tumors: current insights. Onco Targets Ther. 2017 Jul 26;10:3755-3772. doi: 10.2147/OTT.S113119. eCollection 2017. PMID: 28794640; PMCID: PMC5538686.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 285 entries